HighVista Strategies’s BeOne Medicines Ltd ONC Stock Holding History

HighVista Strategies’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,002	Closed	-$378K	–	118
2022 Q1	$378K	Sell	2,002 -578	-22%	-$123K	0.24%	82
2021 Q4	$699K	Sell	2,580 -1,969	-43%	-$665K	0.56%	58
2021 Q3	$1.65M	Buy	4,549 +2,318	+104%	+$758K	1.09%	16
2021 Q2	$766K	Hold	2,231	–	–	0.54%	59
2021 Q1	$777K	Buy	+2,231	New	+$739K	0.58%	32

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

HighVista Strategies's ONC Position: Q2 2022 in Review

HighVista Strategies sold out of BeOne Medicines Ltd (ONC) in Q2 2022, closing a stake of 2,002 shares — an estimated $378K sold.

HighVista Strategies first reported a position in ONC in Q1 2021 and held it in 5 quarters. The position peaked at $1.65M in Q3 2021. 235 funds tracked by Wall St. Rank hold ONC as of Q2 2022.

HighVista Strategies reported no remaining BeOne Medicines Ltd position as of Q2 2022 after selling out during the quarter.
HighVista Strategies sold 2,002 BeOne Medicines Ltd shares in Q2 2022, an estimated $378K.
HighVista Strategies first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 5 quarters.
HighVista Strategies's BeOne Medicines Ltd position peaked at $1.65M in Q3 2021.
235 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2022.

Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.